Trial · NCT03440385
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score < 150 | Ozanimod | 29.8 | percentage of participants | ||
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score < 150 | Placebo | 30.5 | percentage of participants | ||
| Percentage of Participants With Abdominal Pain and Stool Frequency Clinical Remission | Ozanimod | 29.0 | percentage of participants | ||
| Percentage of Participants With Abdominal Pain and Stool Frequency Clinical Remission | Placebo | 26.6 | percentage of participants | ||
| Percentage of Participants With a Simple Endoscopic Score for Crohn's Disease (SES-CD) Score Decrease From Baseline of ≥ 50% | Ozanimod | 25.6 | percentage of participants | ||
| Percentage of Participants With a Simple Endoscopic Score for Crohn's Disease (SES-CD) Score Decrease From Baseline of ≥ 50% | Placebo | 21.2 | percentage of participants | ||
| Percentage of Participants With Reduction From Baseline in the Crohn's Disease Activity Index (CDAI) Score of >= 100 Points or a Total CDAI Score < 150 | Ozanimod | 46.2 | percentage of participants | ||
| Percentage of Participants With Reduction From Baseline in the Crohn's Disease Activity Index (CDAI) Score of >= 100 Points or a Total CDAI Score < 150 | Placebo | 47.3 | percentage of participants | ||
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score Reduction From Baseline of ≥ 100 Points or CDAI Score < 150 and SES-CD Decrease From Baseline of ≥ 50% | Ozanimod | 16.9 | percentage of participants | ||
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score Reduction From Baseline of ≥ 100 Points or CDAI Score < 150 and SES-CD Decrease From Baseline of ≥ 50% | Placebo | 14.3 | percentage of participants | ||
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score < 150 and Simple Endoscopic Score for Crohn's Disease (SES-CD) Score Decrease From Baseline of ≥ 50% | Ozanimod | 11.7 | percentage of participants | ||
| Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score < 150 and Simple Endoscopic Score for Crohn's Disease (SES-CD) Score Decrease From Baseline of ≥ 50% | Placebo | 11.3 | percentage of participants | ||
| Percentage of Participants With Abdominal Pain and Stool Frequency Clinical Remission and a Simple Endoscopic Score for Crohn's Disease (SES-CD) Score <= 4 Points and Decrease >= 2 Points | Ozanimod | 10.4 | percentage of participants | ||
| Percentage of Participants With Abdominal Pain and Stool Frequency Clinical Remission and a Simple Endoscopic Score for Crohn's Disease (SES-CD) Score <= 4 Points and Decrease >= 2 Points | Placebo | 8.4 | percentage of participants | ||
| Percentage of Participants With Global Histologic Activity Score (GHAS) Remission | Ozanimod | 13.6 | percentage of participants | ||
| Percentage of Participants With Global Histologic Activity Score (GHAS) Remission | Placebo | 10.8 | percentage of participants | ||
| Percentage of Participants With CDAI Reduction From Baseline of >=70 Points | Ozanimod | 52.9 | percentage of participants | ||
| Percentage of Participants With CDAI Reduction From Baseline of >=70 Points | Placebo | 51.7 | percentage of participants | ||
| Percentage of Participants With Absence of Ulcers ≥ 0.5 cm With no Segment With Any Ulcerated Surface ≥10% | Ozanimod | 25.3 | percentage of partiicpants | ||
| Percentage of Participants With Absence of Ulcers ≥ 0.5 cm With no Segment With Any Ulcerated Surface ≥10% | Placebo | 24.1 | percentage of partiicpants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03440385/results